ARCHIVES

New FDA Commisioner’s Top Priorities: FDAMA Implimitation, Agency’s Science

This article is from The Cancer Letter archive.

Vol. 25 No. 01 | January 8, 1999

Download PDF Visit The Full Archive

Related Articles

Afinitor and Sutent Approved For Pancreatic Neuroendocrine Tumors

May 27, 2011

The Philadelphia Story: How Surprise Filing by Abramson Spurred Penn to Follow Suit

March 16, 2012

GAO Report To Include Some But Not all Of Obey’s Charges

June 24, 1977

Senate Confirms McClellan For FDA

October 25, 2002

IOM, NCI Clash Over Proposed Change in Tabulating Minority Research

January 22, 1999

NCI Director Broder, Going On 3rd Year, Examines Issues Of Funding, Priorities, For Institute’s Future

September 20, 1991